Hillstream BioPharma (HILS) Competitors $1.35 +0.03 (+2.27%) As of 08/15/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock HILS vs. VIRI, WHWK, OSTX, PYRGF, ATNM, ELYM, NBRV, AADI, EGRX, and NNVCShould you be buying Hillstream BioPharma stock or one of its competitors? The main competitors of Hillstream BioPharma include Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), OS Therapies (OSTX), PyroGenesis Canada (PYRGF), Actinium Pharmaceuticals (ATNM), Eliem Therapeutics (ELYM), Nabriva Therapeutics (NBRV), Aadi Bioscience (AADI), Eagle Pharmaceuticals (EGRX), and NanoViricides (NNVC). Hillstream BioPharma vs. Its Competitors Virios Therapeutics Whitehawk Therapeutics OS Therapies PyroGenesis Canada Actinium Pharmaceuticals Eliem Therapeutics Nabriva Therapeutics Aadi Bioscience Eagle Pharmaceuticals NanoViricides Hillstream BioPharma (NASDAQ:HILS) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings. Which has preferable valuation & earnings, HILS or VIRI? Virios Therapeutics is trading at a lower price-to-earnings ratio than Hillstream BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHillstream BioPharmaN/AN/A-$8.47M-$0.72-1.88Virios TherapeuticsN/AN/A-$5.30M-$0.27-18.26 Which has more risk and volatility, HILS or VIRI? Hillstream BioPharma has a beta of 3.08, meaning that its stock price is 208% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Does the media refer more to HILS or VIRI? In the previous week, Hillstream BioPharma's average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score. Company Overall Sentiment Hillstream BioPharma Neutral Virios Therapeutics Neutral Do insiders and institutionals have more ownership in HILS or VIRI? 13.4% of Hillstream BioPharma shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 30.2% of Hillstream BioPharma shares are held by insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is HILS or VIRI more profitable? Virios Therapeutics' return on equity of -130.33% beat Hillstream BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Hillstream BioPharmaN/A -188.44% -149.61% Virios Therapeutics N/A -130.33%-115.00% Do analysts recommend HILS or VIRI? Virios Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 1.42%. Given Virios Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Virios Therapeutics is more favorable than Hillstream BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryVirios Therapeutics beats Hillstream BioPharma on 6 of the 10 factors compared between the two stocks. Get Hillstream BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HILS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HILS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HILS vs. The Competition Export to ExcelMetricHillstream BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.76M$778.25M$5.72B$9.79BDividend YieldN/A4.84%3.91%4.13%P/E Ratio-1.881.1831.1425.06Price / SalesN/A25.64417.8391.01Price / CashN/A19.5636.7858.67Price / Book2.816.599.086.18Net Income-$8.47M-$4.67M$3.26B$265.11M7 Day Performance9.40%3.22%7.39%4.22%1 Month Performance-17.18%3.30%4.22%0.77%1 Year Performance-54.24%15.26%30.30%24.69% Hillstream BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HILSHillstream BioPharmaN/A$1.35+2.3%N/A-55.0%$23.76MN/A-1.881Gap DownVIRIVirios TherapeuticsN/A$4.85+1.7%$5.00+3.1%+2,508.5%$93.40MN/A-17.965WHWKWhitehawk TherapeuticsN/A$1.71flatN/AN/A$80.59M$25.98M-28.5040OSTXOS Therapies2.2665 of 5 stars$1.88+5.6%$18.00+857.4%-40.8%$52.82MN/A-2.19N/ANews CoverageUpcoming EarningsPYRGFPyroGenesis CanadaN/A$0.27-0.8%N/A-56.9%$51.37M$9.14M-4.5790Gap DownATNMActinium Pharmaceuticals2.9528 of 5 stars$1.60+6.0%$4.50+181.3%-7.1%$49.91MN/A-1.1530News CoveragePositive NewsShort Interest ↓Analyst RevisionELYMEliem TherapeuticsN/A$1.61-2.4%N/A-69.1%$47.90MN/A-3.049NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070AADIAadi Bioscience0.5113 of 5 stars$1.71+1.2%$1.67-2.5%+8.8%$42.23M$25.07M-0.7540EGRXEagle PharmaceuticalsN/A$3.20flatN/AN/A$41.56M$257.55M0.00100NNVCNanoViricides0.3099 of 5 stars$1.50-2.6%N/A-30.4%$24.11MN/A-2.0820 Related Companies and Tools Related Companies VIRI Competitors WHWK Competitors OSTX Competitors PYRGF Competitors ATNM Competitors ELYM Competitors NBRV Competitors AADI Competitors EGRX Competitors NNVC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HILS) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hillstream BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hillstream BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access